|Videos|October 6, 2016

Immunotherapy Combinations Under Investigation in NSCLC

Roy S. Herbst, MD, PhD, discusses the immunotherapy combinations under investigation in NSCLC during the IASLC Chicago Multidisciplinary Symposium in Thoracic Oncology.

Stay up to date on practice-changing data in community practice.

Related to this article

October 10th, 2026

Psilocybin-Assisted Therapy Aims at Existential Distress in Lung Cancer

Theodore Wagener, PhD, of The Ohio State University discusses the design of the phase 2 DREAM LUNG study of psilocybin-assisted therapy for depression in non–small cell lung cancer.

October 18th, 2026

2026 AACR Report Highlights Advances and New Directions in Cancer Treatment

Breakthrough targeted therapies—from KRAS and PROTACs to CAR T—plus ctDNA monitoring and personalized vaccines push earlier detection and smarter cancer treatment.

October 17th, 2026

Weighing Logistics and Time Savings of Subcutaneous Drug Delivery

J. Thaddeus Beck, MD, discusses how the shift from intravenous to subcutaneous formulations is changing oncology practice, from clinic logistics to patient preferences.

October 16th, 2026

Dr Simmons on Payer Barriers and Safety in Community-Based CAR T-Cell Therapy

Gary Simmons, DO, MSHA, discusses outpatient CAR T-cell therapy in the community, the operational and payer bottlenecks his practice has faced, and advice for colleagues.

October 14th, 2026

Insurance Hurdles Complicate Febrile Neutropenia Prevention in ES-SCLC

During a live event, Mary Jo Fidler, MD, and participants discussed how an intermediate-risk regimen, insurance resistance, and limited experience with trilaciclib shape neutropenia prevention in extensive-stage disease.

October 14th, 2026

AACR Report Highlights Gains in Cancer Survival and Prevention

Cancer deaths keep falling as survival rises, fueled by prevention, early detection, and therapies—yet gaps persist, and research funding uncertainty threatens future gains.